The Events Leading to the Brexit & What It Means for Pharma’s Future


Stephan Rau cited “financial turmoil in EU since 2008 and a growing perception of migrant crisis” as reasons for Britain’s Brexit vote. For UK pharmaceutical companies, he continued, EU membership increased cost and reduced risk appetite due to “complex regulations, uncertainty over the future of the euro, taxation issues, and restrictive employment laws,” but also provided access to a large single market.